In Bavaria, Germany, CEO Philip Schetter of Cantourage recently showcased the company’s cannabis production facility, which is secured by a robust 75-centimeter thick steel door. This facility is part of Cantourage’s strategy to produce and distribute cannabis-based medicinal products in a tightly regulated environment.
Cantourage specializes in the cultivation and distribution of cannabis for medical purposes, adhering to strict German laws governing the industry. As the demand for medicinal cannabis continues to rise, the company is positioned to meet this need by ensuring high safety standards and regulatory compliance.
During a recent tour of the facility, Schetter emphasized the importance of security in protecting their products, stating, “Better safe than sorry.” This highlights the company’s commitment to safeguarding their cannabis stock and maintaining the integrity of their operations.
Germany’s medicinal cannabis market has seen significant growth since the legalization of medical cannabis in 2017. The country now has a network of licensed producers and distributors that cater to patients who require cannabis for various health issues, including chronic pain and epilepsy.
Cantourage’s facility is equipped with advanced technology for cultivation and processing, ensuring a consistent supply of high-quality cannabis. The company aims to be at the forefront of the medicinal cannabis sector in Europe, which is expected to expand further in the coming years.
As the market evolves, Cantourage continues to explore new opportunities to innovate within the industry, further solidifying its position as a leader in the German pharmaceutical cannabis landscape.
English 
Spanish 
German 
Czech